256 related articles for article (PubMed ID: 24922575)
1. The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design.
van Sorge NM; Cole JN; Kuipers K; Henningham A; Aziz RK; Kasirer-Friede A; Lin L; Berends ETM; Davies MR; Dougan G; Zhang F; Dahesh S; Shaw L; Gin J; Cunningham M; Merriman JA; Hütter J; Lepenies B; Rooijakkers SHM; Malley R; Walker MJ; Shattil SJ; Schlievert PM; Choudhury B; Nizet V
Cell Host Microbe; 2014 Jun; 15(6):729-740. PubMed ID: 24922575
[TBL] [Abstract][Full Text] [Related]
2. Virulence Role of the GlcNAc Side Chain of the Lancefield Cell Wall Carbohydrate Antigen in Non-M1-Serotype Group A
Henningham A; Davies MR; Uchiyama S; van Sorge NM; Lund S; Chen KT; Walker MJ; Cole JN; Nizet V
mBio; 2018 Jan; 9(1):. PubMed ID: 29382733
[TBL] [Abstract][Full Text] [Related]
3. Immunobiology of the Classical Lancefield Group A Streptococcal Carbohydrate Antigen.
Gao NJ; Rodas Lima E; Nizet V
Infect Immun; 2021 Nov; 89(12):e0029221. PubMed ID: 34543125
[TBL] [Abstract][Full Text] [Related]
4. The molecular mechanism of
Rush JS; Edgar RJ; Deng P; Chen J; Zhu H; van Sorge NM; Morris AJ; Korotkov KV; Korotkova N
J Biol Chem; 2017 Nov; 292(47):19441-19457. PubMed ID: 29021255
[TBL] [Abstract][Full Text] [Related]
5. A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes.
Bi S; Xu M; Zhou Y; Xing X; Shen A; Wang B
mBio; 2019 Nov; 10(6):. PubMed ID: 31772056
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.
Pandey M; Mortensen R; Calcutt A; Powell J; Batzloff MR; Dietrich J; Good MF
J Immunol; 2016 Apr; 196(8):3364-74. PubMed ID: 26969753
[TBL] [Abstract][Full Text] [Related]
7. Opacity factor activity and epithelial cell binding by the serum opacity factor protein of Streptococcus pyogenes are functionally discrete.
Gillen CM; Courtney HS; Schulze K; Rohde M; Wilson MR; Timmer AM; Guzman CA; Nizet V; Chhatwal GS; Walker MJ
J Biol Chem; 2008 Mar; 283(10):6359-66. PubMed ID: 18180300
[TBL] [Abstract][Full Text] [Related]
8. T4 Pili Promote Colonization and Immune Evasion Phenotypes of Nonencapsulated M4 Streptococcus pyogenes.
Chen YH; Li SH; Yang YC; Hsu SH; Nizet V; Chang YC
mBio; 2020 Jul; 11(4):. PubMed ID: 32694142
[No Abstract] [Full Text] [Related]
9. Group A
Young PG; Raynes JM; Loh JM; Proft T; Baker EN; Moreland NJ
Infect Immun; 2019 Jun; 87(6):. PubMed ID: 30936156
[TBL] [Abstract][Full Text] [Related]
10. Cellular interactions of covR/S mutant group A Streptococci.
Langshaw EL; Pandey M; Good MF
Microbes Infect; 2018; 20(9-10):531-535. PubMed ID: 29287985
[TBL] [Abstract][Full Text] [Related]
11. Streptococcal Lancefield polysaccharides are critical cell wall determinants for human Group IIA secreted phospholipase A2 to exert its bactericidal effects.
van Hensbergen VP; Movert E; de Maat V; Lüchtenborg C; Le Breton Y; Lambeau G; Payré C; Henningham A; Nizet V; van Strijp JAG; Brügger B; Carlsson F; McIver KS; van Sorge NM
PLoS Pathog; 2018 Oct; 14(10):e1007348. PubMed ID: 30321240
[TBL] [Abstract][Full Text] [Related]
12. D-alanylation of teichoic acids promotes group a streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion.
Kristian SA; Datta V; Weidenmaier C; Kansal R; Fedtke I; Peschel A; Gallo RL; Nizet V
J Bacteriol; 2005 Oct; 187(19):6719-25. PubMed ID: 16166534
[TBL] [Abstract][Full Text] [Related]
13. Group A, B, C, and G
Zorzoli A; Meyer BH; Adair E; Torgov VI; Veselovsky VV; Danilov LL; Uhrin D; Dorfmueller HC
J Biol Chem; 2019 Oct; 294(42):15237-15256. PubMed ID: 31506299
[TBL] [Abstract][Full Text] [Related]
14. M protein and hyaluronic acid capsule are essential for in vivo selection of covRS mutations characteristic of invasive serotype M1T1 group A Streptococcus.
Cole JN; Pence MA; von Köckritz-Blickwede M; Hollands A; Gallo RL; Walker MJ; Nizet V
mBio; 2010 Aug; 1(4):. PubMed ID: 20827373
[TBL] [Abstract][Full Text] [Related]
15. Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection.
Sabharwal H; Michon F; Nelson D; Dong W; Fuchs K; Manjarrez RC; Sarkar A; Uitz C; Viteri-Jackson A; Suarez RS; Blake M; Zabriskie JB
J Infect Dis; 2006 Jan; 193(1):129-35. PubMed ID: 16323141
[TBL] [Abstract][Full Text] [Related]
16. Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.
Rivera-Hernandez T; Pandey M; Henningham A; Cole J; Choudhury B; Cork AJ; Gillen CM; Ghaffar KA; West NP; Silvestri G; Good MF; Moyle PM; Toth I; Nizet V; Batzloff MR; Walker MJ
mBio; 2016 Jun; 7(3):. PubMed ID: 27302756
[TBL] [Abstract][Full Text] [Related]
17. Structure-informed design of an enzymatically inactive vaccine component for group A Streptococcus.
Henningham A; Ericsson DJ; Langer K; Casey LW; Jovcevski B; Chhatwal GS; Aquilina JA; Batzloff MR; Kobe B; Walker MJ
mBio; 2013 Aug; 4(4):. PubMed ID: 23919999
[TBL] [Abstract][Full Text] [Related]
18. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
19. A Critical Role of Zinc Importer AdcABC in Group A Streptococcus-Host Interactions During Infection and Its Implications for Vaccine Development.
Makthal N; Nguyen K; Do H; Gavagan M; Chandrangsu P; Helmann JD; Olsen RJ; Kumaraswami M
EBioMedicine; 2017 Jul; 21():131-141. PubMed ID: 28596134
[TBL] [Abstract][Full Text] [Related]
20. Contribution of cryptic epitopes in designing a group A streptococcal vaccine.
Ozberk V; Pandey M; Good MF
Hum Vaccin Immunother; 2018; 14(8):2034-2052. PubMed ID: 29873591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
